BCIQ Profiles

Company Profile Report
0812 GigaGen COVID
BioCentury & Getty Images

Product Development

GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute

Plus SAB gets additional funding from U.S. government, starts human trials

Aug 13, 2020 | 1:48 AM GMT

GigaGen is developing polyclonal antibodies for COVID-19 and

Read the full 441 word article

How to gain access

Continue reading with a
two-week free trial.